EP1190042A2 - Procedes servant a manipuler le genome aviaire - Google Patents
Procedes servant a manipuler le genome aviaireInfo
- Publication number
- EP1190042A2 EP1190042A2 EP00943424A EP00943424A EP1190042A2 EP 1190042 A2 EP1190042 A2 EP 1190042A2 EP 00943424 A EP00943424 A EP 00943424A EP 00943424 A EP00943424 A EP 00943424A EP 1190042 A2 EP1190042 A2 EP 1190042A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleic acid
- polypeptide
- egg
- avian
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 241000271566 Aves Species 0.000 title claims abstract description 42
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 65
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 55
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 55
- 241001465754 Metazoa Species 0.000 claims abstract description 8
- 238000001727 in vivo Methods 0.000 claims abstract description 8
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 4
- 230000009261 transgenic effect Effects 0.000 claims abstract 5
- 241000287828 Gallus gallus Species 0.000 claims description 39
- 108700019146 Transgenes Proteins 0.000 claims description 38
- 235000013330 chicken meat Nutrition 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 230000001105 regulatory effect Effects 0.000 claims description 21
- 210000002298 blastodisc Anatomy 0.000 claims description 19
- 108090001061 Insulin Proteins 0.000 claims description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 15
- 102000004877 Insulin Human genes 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 12
- 230000017448 oviposition Effects 0.000 claims description 10
- 108010014251 Muramidase Proteins 0.000 claims description 9
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 7
- 108010051696 Growth Hormone Proteins 0.000 claims description 6
- 108010071390 Serum Albumin Proteins 0.000 claims description 6
- 102000007562 Serum Albumin Human genes 0.000 claims description 6
- 241000286209 Phasianidae Species 0.000 claims description 5
- 239000011435 rock Substances 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 3
- 241000272525 Anas platyrhynchos Species 0.000 claims description 2
- 241000272814 Anser sp. Species 0.000 claims description 2
- 241000726096 Aratinga Species 0.000 claims description 2
- 241000721631 Nymphicus hollandicus Species 0.000 claims description 2
- 241000220010 Rhode Species 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 102000055006 Calcitonin Human genes 0.000 claims 3
- 108060001064 Calcitonin Proteins 0.000 claims 3
- 102000018997 Growth Hormone Human genes 0.000 claims 3
- 241001494315 Cacatuidae Species 0.000 claims 1
- 101150073877 egg-1 gene Proteins 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 235000013601 eggs Nutrition 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 28
- 210000001172 blastoderm Anatomy 0.000 description 24
- 239000012528 membrane Substances 0.000 description 14
- 108010000912 Egg Proteins Proteins 0.000 description 13
- 102000002322 Egg Proteins Human genes 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000004048 modification Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 210000004681 ovum Anatomy 0.000 description 9
- 210000003278 egg shell Anatomy 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 6
- 108010058846 Ovalbumin Proteins 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 210000002969 egg yolk Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 102000016943 Muramidase Human genes 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 102000050459 human LTF Human genes 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229960000274 lysozyme Drugs 0.000 description 4
- 239000004325 lysozyme Substances 0.000 description 4
- 235000010335 lysozyme Nutrition 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229940092253 ovalbumin Drugs 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 108020005065 3' Flanking Region Proteins 0.000 description 3
- 101000751233 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) 50S ribosomal protein L21e Proteins 0.000 description 3
- 108010063045 Lactoferrin Proteins 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000000994 inner shell membrane Anatomy 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010005991 Pork Regular Insulin Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000287531 Psittacidae Species 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108010026206 Conalbumin Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 210000004997 mammalian reproductive system Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000996 thick albumen Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/30—Bird
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/90—Vector systems having a special element relevant for transcription from vertebrates avian
Definitions
- the invention relates to transgemc avian animals
- the invention features methods of manipulating genomic DNA m avian species and to generate transgemc avian animals
- a method for introducing a nucleic acid molecule into the genome of an avian species is earned out bv contacting in vivo a blastodermal cell of a fertilized hard shelled egg with the nucleic acid molecule
- the nucleic acid molecule is not associated with a viral coat protem, e g , the nucleic acid is not delivered in a ⁇ iral particle
- the nucleic acid molecule is introduced directly into the germinal disc of the egg To avoid disrupting the germinal disc (or blastoderm) or dispersing the blastodermal cells, the nucleic acid is delivered in a volume that is less than the volume of the germinal disc
- the volume is greater than 1 microhter and less than 0 5 milliliters and introduction of the nucleic acid does not rupture the area opaca (membrane or sheath surrounding the germinal disc or blastoderm)
- the nucleic acid is delivered in a volume of 5-100 microhters, more preferably 40-60 microhters. and most preferably.
- the nucleic acid is delivered directly into the blastoderm or germinal disc and not to an area adjacent to or below the blastoderm
- the thick albumen around the germinal disc is not removed before, du ⁇ ng, or after the delivery process
- the nucleic acid is delivered by passing a needle or microinjection pipet directly through the shell and underlying membrane Little or no air is introduced into the egg, and the hole m the membrane left by the pipet or needle is small and self-sealing Accordingly, the method does not require deposition of an aqueous liquid o ⁇ er the opening of the egg to minimize the inadvertent introduction of air into the egg and does not require sealing the opening of the egg after nucleic acid delivery
- the blastodermal cell is exposed to an electncal current in vivo, e g , by applying an electncal current across the egg
- the method is useful to introduce a nucleic acid such as DNA into the genome of any avian species such as a chicken, an ostnch. an emu, a turkeys, a duck, a goose, a quail a parrot, a parakeet, a cockatoo, or a cockatiel to produce therapeutic proteins or to make an avian model for a non-avian, e g , human, disease state
- the method is used to deliver DNA to blastodermal cells in a fertilized egg of any breed of chicken or any hyb ⁇ d breed of chicken Chicken breeds include White Leghorn, White Neighborhood Rock, Barred Neighborhood Rock, Rhode Island Red, New Hampshire and Dark Cornish
- Nucleic acid delivery is timed to optimize uptake of the nucleic acid by blastodermal (totipotent) cells and minimize (or eliminate) uptake by cells which have begun to differentiate into vanous tissue types
- blastodermal totipotent
- nucleic acid dunng developmental stage X of the egg Delivery takes place at a time after oviposition but before incubation of the egg (at which time cell division and cell differentiation takes place)
- the nucleic acid encodes a polypeptide or antisense molecule
- the nucleic acid contains a sequence encoding an antibody or fragment thereof
- the term antibody encompasses an mtact tetramenc antibody (e g , a monoclonal antibody) as well as an immunologically active antibody fragment, e g , a Fab or (Fab) 2 fragment, an engineered single chain F, molecule, a chime ⁇ c molecule (e g , an antibody which contains the binding specificity of one antibody, e g , of munne origin, and the remaining portions of another antibody, e g , of human o ⁇ gin
- the antibody or fragment thereof is of human ongm
- Other polypeptides include an insulin polypeptide (such as a human or porcine insulin polypeptide), a growth hormone polypeptide, a calcitonm polypeptide, or a serum albumin polypeptide
- the transgemc nucleic acid encodes a porcine
- Transcnptional regulatory sequence is a gene ⁇ c term used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences to which they are operably linked
- Transc ⁇ ption of the recombinant gene or transgene is under the control of a promoter sequence as well as other transcnptional regulatory sequences
- an ovalbumin promoter sequence is used to direct expression of a transgene and a regulatory sequences de ⁇ ved from a chicken lysozvme gene is used to direct equal or equivalent expression of both chains of a transgemc tetrame ⁇ c antibody molecule
- promoter is meant a minimal DNA sequence sufficient to direct transc ⁇ ption Promoters may be constitutive or inducible, and may be coupled to other regulatory sequences or "elements" which render promoter-dependent gene expression cell-type specific, tissue-specific or mducible by external signals or agents, such elements may be located in the 5' or 3' region of the native gene, or withm an intron
- a transgene expression construct contains one or more of the following elements a chicken lysozyme or ovalbumin promoter, a chicken lysozyme enhancer, and a mat
- nucleic acids described herein are isolated An isolated nucleic acid, e g , an isolated gene, or a fragment thereof, to be transfe ⁇ ed into a blastodermal cell of an egg is isolated by any of several methods well known to the art
- the nucleic acid molecules are recombinant and/or have been pu ⁇ fied from the sequences which flank it in a naturally occur ⁇ ng state, I e a DNA has been removed from the sequences which are normally adjacent to the fragment, e g , the sequences adjacent to the fragment in the genome in which it naturally occurs
- an isolated nucleic acid molecule is produced synthetically, or by treating mRNA de ⁇ ved from the transc ⁇ ption of the gene with a reverse transc ⁇ ptase so as to produce a cDNA, or by the direct isolation of the nucleic acid from cells, bacte ⁇ al clones, or from other sources
- the invention includes sequences which hyb ⁇ dize under st ⁇ ngent conditions, with all
- Nucleotide and ammo acid compa ⁇ sons are earned out using the Lasergene software package (DNASTAR, Inc , Madison, WI)
- the MegA gn module used was the Clustal V method (Higgins et al , 1989, CABIOS 5(2) 151-153) The parameter used were gap penalty 10, gap length penalty 10
- the nucleic acids descnbed herein hyb ⁇ dize at high st ⁇ ngency to a strand of DNA having the reference sequence, or the complement thereof and have transcnption regulatory activity Hyb ⁇ dization is earned out using standard techniques, such as those desc ⁇ bed in Ausubel et al (Cu ⁇ ent Protocols in Molecular Biology, John Wiley & Sons, 1989)
- "High stnngency" refers to nucleic acid hyb ⁇ dization and wash conditions characte ⁇ zed by high temperature and low salt concentration, 1 e, hyb ⁇ dization at 42 degrees C, and in 50% formamide, a first
- Fig 1 is a diagram of a fertilized hen's egg
- Fig 2 is a diagram of a transgene expression cassette DETAILED DESCRIPTION OF THE INVENTION
- the avian reproductive system is distinct from mammalian reproductive systems in that the female can store sperm and fertilize a single ovum at a time
- the new fertilized ovum is large, fragile, and filled with yolk as it enters the reproductive track
- Early embryonic development occurs in the oviduct as the egg is formed around the ovum
- a protective layer of white albumen followed by an inner membrane and hardened shell before being laid (Fig 1 )
- the ovum has matured from a single cell into a blastoderm (also known as the germinal disc) composed of 40-60,000 cells and development a ⁇ ests until the hen has laid enough eggs and beings to roost In the blastoderm state, all cells are totipotent and equally capable of cont ⁇ butmg to the germ line of the developing chick
- Oviposition is the time at which the egg is laid In the chicken, oviposition occurs at stage X (a freshly laid egg, about 20 hours of utenne age)
- stage X a freshly laid egg, about 20 hours of utenne age
- DNA is therefore introduced into the blastoderm of an egg which has been incubated for 6 hours or less
- stage X refers to a stage of development that occurs at about 20 hours ute ⁇ ne age and is charactenzed by oviposition
- stage 10 refers to a stage of embryonic chick development (charactenzed by tissue differentiation) No tissue differentiation has occu ⁇ ed in stage X of development Accordingly, genetic manipulation occurs before differentiation of blastodermal cells into embryonic
- the germinal disc is distinguished from the germinal crescent region in that the germinal disc contains undifferentiated blastodermal cells (at stage X or before), whereas the germinal crescent region appears in the early stages of chick embryo development (I e , stages 3-5 or 9-1 1 of chick embryo development)
- the cells of the blastoderm are genetically manipulated both in vitro or in vivo using gene delivery techniques and then used to produce transgemc or chime ⁇ c chickens by allowing development in the egg, transfernng to a recipient unfertilized egg, or transfer ⁇ ng to the testes of a ste ⁇ le rooster for development into spermatogonia
- the optimum time for transfection is between oviposition and several hours of activation of the egg in order to reduce the number of target cells for transfection
- the blastoderm is accessed by cutting or d ⁇ lling a small hole in the egg shell (sitting upnght) with a scapel or dnll and gently peeling back the inner membrane to expose the white albumen
- the blastoderm automatically onents to the top of the yolk and is visualized under light
- the cells of the blastoderm are transfected in v ⁇ o by infusing DNA directly into the blastoderm using a synnge and small gauge needle
- the DNA is naked or complexed with pids or other suitable compounds to facility DNA uptake (e g , DEAE-dextran) If the DNA is naked, the transfection efficiency is increased by passing an electncal current across the blastoderm or whole egg with a device such as a human heart defib ⁇ llator If a current is passed across the whole egg, two additional holes are made in the egg shell to expose the inner membrane to the cu ⁇ ent since the shell will not conduct elect ⁇ city
- the blastoderm is removed from the egg and pooled with the cells from several eggs using a small pipet
- DNA uptake by blastodermal cells is facilitated by such techniques as electroporation, DEAE-dextran treatment, calcium phosphate treatment, or pofection
- the cells are transferred into the germinal disc of an unfertilized egg for development of a transgemc chick or into the testes of a ste ⁇ le rooster to induce development in spermatogonia and sperm for breeding
- Chicks produced are tested for the presence of the transgene according to known methods, e g, by the polymerase chain reaction or southern blot analysis
- the overall efficiency of the nucleic acid delivery procedure depends on the method and timing of gene delivery Transfection efficiency is optionally increase by methods such as
- Prefe ⁇ ed transgene constructs include those carrying the ovalbumin promoter operatively linked to the human serum albumin gene
- Fertilized eggs are laid and collected (day 1 )
- the eggs are shipped at room temperature (umncubated) (day 2)
- the eggs are allowed to site upnght for at least
- a fertilized hen's egg was collected and placed in a humidified incubator for between 1 and 6 hours to activate the egg
- a hole was cut in the egg shell using a dremel and the inner membrane was folded back
- the egg was placed on a light to visualize the germinal disc which was infused with a hpid/DNA complex
- the inner membrane was folded into place and the egg sealed with parafilm
- the egg was placed back into the incubator and allowed to develop to term ⁇ blood sample or inner membrane sample as taken from the resulting chick and tested for the presence of the transgene by the polymerase chain reaction with transgene specific p ⁇ mers
- a mosaic or chime ⁇ c chick is bred to a rooster to produce fully transgemc offsp ⁇ ng
- Example 2 In vitro DNA delivery of blastodermal cells and transfer of transfected eggs to an unfertilized egg
- a genomic sequence encoding human insulin was operatively linked to a promoter which directs transcription of a nucleic acid to which it is operably linked in avian eggs.
- the promoter is a human lactoferrin promoter.
- transcription regulatory elements are derived from a milk specific promoter, e.g., a mammalian lactoferrin gene promoter.
- the expression cassette contains a promoter region derived from the human lactoferrin gene operably linked to a heterologous sequence.
- a heterologous sequence is one that does not encode a lactoferrin polypeptide.
- the promoter region includes at least 20 nucleotides of the nucleotide sequence of SEQ ID NO:l .
- the promoter region contains nucleotides 1 -154 of SEQ ID NO: 1 or 2.
- BamHl restriction site GGATCC (nucleotides 5-8) and Xhol site (nucleotides 140- 145) are italicized. These restriction sites may be altered, e.g., replaced with other restriction sites or with nucleotides that do not represent restriction enzyme recognition sites.
- Table 2 Human Lactoferrin promoter region
- lactoferrin-derived promoter regions described above are linked to the nucleotide sequence of SEQ ID NO:3 (GENBA KTM accession no. S52659).
- isolated is meant a nucleic acid molecule that is free of the genes which, m the naturally-occumng genome of the organism, flank the sequence of interest
- isolated includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a procaryote or eucaryote; or which exists as a separate molecule (e g , a cDNA or a genomic or cDNA fragment produced by PCR or rest ⁇ ction endonuclease digestion) independent of other sequences.
- telomere sequence which is part of a hyb ⁇ d gene encoding additional polypeptide sequence
- the term excludes large segments of genomic DNA, e g , such as those present in cosmid clones, which contain a given DNA sequence flanked by one or more other genes which naturally flank it in a naturally-occumng genome Lactofemn-de ⁇ ved transc ⁇ ption regulatory sequences, are attached to a nominal promoter (e g , the nominal lactofermn promoter or a heterologous promoter) which in turn is operably linked to a sequence to be transc ⁇ bed
- the heterologous sequence to be transc ⁇ bed is a polypeptide-encodmg sequence or antisense sequence
- the regulatory sequences of the invention operably linked to a polypeptide-encodmg sequence direct production of the encoded polypeptide m avian tissues
- nucleic acid fragment is a portion of at least 20 continuous nucleotides identical to a portion of length equivalent to one of the reference nucleotide sequences or to its complement
- promoters which direct transcnption m eggs of an avian animal are known in the art, e g , the chicken ovalbumin promoter (GENBANKTM J00895 or M24999) and the chicken lysozyme promoter (GENBANKTM J00886 or V00429)
- An expression vector is constructed using a chicken ovalbumin promoter for expression of cloned sequences (Gannon et al , Organisation and sequences at the 5 'end of a cloned complete ovalbumin gene Nature 278 428434, Lai et al , The ovalbumin gene Structural sequence m native chicken DNA are not contiguous Proc Natl Acad Sci USA 75(5) 2205-2209, and Kaye et al , EMBO J 3 1 137-1 144)
- Other regulatory elements which direct transcnption of transgenes include a nuclear DNA attachment element which mediates elevated and position-independent gene activity (Stief, A , et al ,
- Protein or polypeptide products to be expressed by the transgene include human insulin (GENBANKTMV00565), human calcitomn (GENBANKTM XI 5943, Broad et al., Nucl Acids Res 17 6999-701 1 ), human serum albumin (GENBANKTM M12523, J04457), and a porcine single chain insulin
- the nucleic acid sequence of the porcine single chain insulin sequence are shown below in Tables 4 and 5
- GCAACTAGACTCGAG SEQ ID NO 4
- the invention includes sequences which hyb ⁇ dize under st ⁇ ngent conditions, with all or part of the sequence reported in a reference sequence and retains transcnption regulatory function
- the nucleic acid may contain one or more sequence modifications in relation to a reference sequence Such modifications may be obtained by mutation, deletion and or addition of one or more nucleotides compared to the reference sequence Modifications are introduced to alter the activity of the regulatory sequence, e g , to improve promoter activity, to suppress a transc ⁇ ption inhibiting region, to make a constitutive promoter regulatable or vice versa Modification are also made to introduce a rest ⁇ ction site facilitating subsequent cloning steps, or to eliminate the sequences which are not essential to the transcnptional activity
- a modified sequence is at least 70% (more preferably at least 80%, more preferably at least 90%, more preferably at least 95%, more preferably at least 99%) identical to a reference sequence The modifications do not substantially alter the transc ⁇ ption promoter function associated with
- a lactofer ⁇ n expression cassette was constructed using lactofer ⁇ n transcnption regulatory elements.
- the cassette contained 3Kb of promoter and 7Kb of 3 ' flanking sequence with unique Sail and Notl rest ⁇ ction sites at the 5 ' and 3 'ends, respectively
- the vector contained a unique Xhol site for the addition of heterologous coding sequences.
- the human insulin gene was PCR amplified from human genomic DNA with the p ⁇ mers HINF3 (5'GCCCTCGAGGACAGGCTGCATCAGAA3 ' ; (SEQ ID NO:6)) H ⁇ NR3 (5'CTCGGTGCTCGAGGCGGCGGGTGT3 ⁇ SEQ ID NO7) cloned into the vector pCR2.1 (Invitrogen, Carlsbad,CA) according to the manufacturer's instructions The gene sequenced using the Amp cycle Sequencing kit (PE Applied Biosystems, Foster City, CA) to confirm that no base mutations had occu ⁇ ed dunng amplification.
- the gene was excised from the vector pCR2.1 as and Xhol fragment and cloned into the Xhol site of the human lactofemn expression cassette. The o ⁇ entation of the insulin gene was confirmed by rest ⁇ ction analysis and DNA sequencing. The completed vector was designated HL31 and could be excised from the bacte ⁇ al backbone as a Sail to Notl fragment Example 6 Preparation of HL31 for Transfection
- the eggshell was removed to expose the inner shell membrane and allow the visualization of the germinal disc. If the germinal disc could not be visualized a small opening was made in the membrane.
- the DNA/lipid solution was injected directly into the center of the disc. Nucleic acid solutions (construct encoding human insulin) were injected in a volume of 50-100 1 with a lcc syringe and 27 gauge needle or in a volume of 10-20 1 with a microinjection needle attached to a Hamilton syringe. Table 6 shows data from representative experiments. 228 eggs were injected and 26 chicks were hatched (Table 6)
- Chimensm of the hatched chicks was tested by PCR analysis of genomic DNA isolated from the inner shell membrane (post-hatching), or the liver, kidney, and reproductive organs upon necropsy (Table 7) Out of the 3 chicks tested in expenment 32, 2 showed a strong PCR signal in the inner shell membrane sample Upon maturation, these chicks are bred to confirm germhne transmission of the transgene PCR analysis of necropsy samples (membrane and reproductive organs) taken from 4 chicks de ⁇ ved from expenments 32 & 33 revealed that 1 out of 4 chicks had detectable levels of the transgene its reproductive organs
- Table 7 shows results from a representative analysis of tissue expression of human insulin transgene in chime ⁇ c chickens produced as descnbed above Table 7 PCR analysis of Genomic DNA Isolated from Chimenc Chicks
- transgenes such as MT-beta-Gal, and CMV-GFP were also transfected into blastodermal cells in vivo Chicks were produced and tested for tissue expression of the transgene as descnbed above The transgemc DNA was detected in the following tissues which were tested heart, liver, and kidney
- the methods of the invention do not utilize retroviral particles Many of those methods use non-rephcatmg retroviruses, which contain a gene of interest, to mfect a developing egg
- This process has several limitations which include a restnction on the size of the gene packaged in the viral coat, and instability of expression from retroviral vectors
- retroviral gene delivery is severely limited in its ability to produce high levels of multime ⁇ c proteins since each coding region w ould optimally require its own promoter
- IRES sequences which allow for bicistromc mRNAs, howev er the expression from these types of constructs is generally low unless a selection marker is used
- the transgene is insulated from the effects of the surrounding chromatin structure by including elements such as mat ⁇ x attachment regions (Step 3 of Fig 2) Unlike p ⁇ or art methods which have utilized mat ⁇ x attachment region, the constructs descnbed herein result in equal expression of multimenc proteins
- the elements are called A-elements, MAR for mat ⁇ x attachment regions, SAR, scaffolding attachment regions, DCR for dominant control region, and insulators.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13776199P | 1999-06-04 | 1999-06-04 | |
US137761P | 1999-06-04 | ||
PCT/US2000/040059 WO2000075300A2 (fr) | 1999-06-04 | 2000-06-02 | Procedes servant a manipuler le genome aviaire |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1190042A2 true EP1190042A2 (fr) | 2002-03-27 |
Family
ID=22478939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00943424A Withdrawn EP1190042A2 (fr) | 1999-06-04 | 2000-06-02 | Procedes servant a manipuler le genome aviaire |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1190042A2 (fr) |
JP (1) | JP2003501083A (fr) |
AU (1) | AU777420B2 (fr) |
CA (1) | CA2375441A1 (fr) |
NZ (1) | NZ516173A (fr) |
WO (1) | WO2000075300A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03001915A (es) | 2000-08-03 | 2004-09-10 | Therapeutic Human Polyclonals | Produccion de anticuerpos humanizados en animales transgenicos. |
US20020108132A1 (en) * | 2001-02-02 | 2002-08-08 | Avigenics Inc. | Production of a monoclonal antibody by a transgenic chicken |
MXPA04001333A (es) | 2001-08-13 | 2004-05-05 | Embrex Inc | Metodos para inyectar huevos de ave. |
WO2003025146A2 (fr) * | 2001-09-18 | 2003-03-27 | Avigenics, Inc. | Production d'oiseaux transgeniques par injection cytoplasmique |
AU2002341795A1 (en) * | 2001-09-21 | 2003-04-01 | Avigenics, Inc. | Production of transgenic avians using sperm-mediated transfection |
US7323618B2 (en) | 2002-02-01 | 2008-01-29 | Origen Therapeutics, Inc. | Tissue specific expression of exogenous proteins in transgenic chickens |
US7145057B2 (en) | 2002-02-01 | 2006-12-05 | Origen Therapeutics, Inc. | Chimeric bird from embryonic stem cells |
US20060191026A1 (en) | 2005-02-18 | 2006-08-24 | Origen Therapeutics, Inc. | Tissue specific expression of antibodies in chickens |
AU2003212958A1 (en) * | 2002-02-08 | 2003-09-02 | Tranxenogen, Inc. | Immunoglobulin purification |
EP1623035A4 (fr) * | 2003-04-15 | 2006-08-30 | Univ Georgia Res Found | Transgenese aviaire utilisant une region du gene de l'ovalbumine du poulet |
MXPA06000562A (es) | 2003-07-15 | 2006-03-30 | Therapeutic Human Polyclonals | Loci de inmunoglobulina humanizada. |
PL2064325T3 (pl) | 2006-09-01 | 2012-05-31 | Therapeutic Human Polyclonals Inc | Zwiększona ekspresja ludzkiej lub humanizowanej immunoglobuliny u zwierząt transgenicznych innych niż człowiek |
IN2014CN02113A (fr) | 2011-09-21 | 2015-05-29 | Fujirebio Kk |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162215A (en) * | 1988-09-22 | 1992-11-10 | Amgen Inc. | Method of gene transfer into chickens and other avian species |
EP0424044A1 (fr) * | 1989-10-16 | 1991-04-24 | Merck & Co. Inc. | Poule transgénique exprimant l'hormone de croissance bovine |
GB2282139A (en) * | 1993-09-24 | 1995-03-29 | Univ Reading | Introducing DNA into the germ line of birds |
AU1812597A (en) * | 1996-07-08 | 1998-02-02 | Dnavec Research Inc. | In vivo electroporation method for early animal embryo |
JP4731683B2 (ja) * | 1997-08-22 | 2011-07-27 | ユニバーシティ・オブ・グエルフ | 卵中でのタンパク質の産生 |
JP2001520009A (ja) * | 1997-10-16 | 2001-10-30 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | 鳥の導入遺伝子についてのマグナム特異的プロモーターを含むベクター |
-
2000
- 2000-06-02 WO PCT/US2000/040059 patent/WO2000075300A2/fr not_active Application Discontinuation
- 2000-06-02 AU AU57898/00A patent/AU777420B2/en not_active Ceased
- 2000-06-02 CA CA002375441A patent/CA2375441A1/fr not_active Abandoned
- 2000-06-02 JP JP2001502566A patent/JP2003501083A/ja not_active Withdrawn
- 2000-06-02 EP EP00943424A patent/EP1190042A2/fr not_active Withdrawn
- 2000-06-02 NZ NZ516173A patent/NZ516173A/xx unknown
Non-Patent Citations (3)
Title |
---|
CARSCIENCE R.S. ET AL: "Germiline chimeric chickens from dispersed donor blastodermal cells and compromised recipient embryos", DEVELOPMENT, vol. 117, 1993, pages 669 - 675, XP000998006 * |
See also references of WO0075300A3 * |
THORAVAL P. ET AL: "Germline transmission of exogenous genes in chicken using helper-free ecotropic avian leukosis virus-based vectors", TRANSGENIC RESEARCH, vol. 4, November 1995 (1995-11-01), pages 369 - 377, XP002095225, DOI: doi:10.1007/BF01973755 * |
Also Published As
Publication number | Publication date |
---|---|
AU5789800A (en) | 2000-12-28 |
AU777420B2 (en) | 2004-10-14 |
NZ516173A (en) | 2004-02-27 |
CA2375441A1 (fr) | 2000-12-14 |
WO2000075300A3 (fr) | 2002-01-10 |
WO2000075300A2 (fr) | 2000-12-14 |
JP2003501083A (ja) | 2003-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5175383A (en) | Animal model for benign prostatic disease | |
US6607884B1 (en) | Methods of detecting growth differentiation factor-8 | |
US7976839B2 (en) | Growth differentiation factor-11 | |
US20020150577A1 (en) | Use of antibodies specific for growth differentiation factor-11 | |
AU669484B2 (en) | Transgenic protein production | |
US20080213426A1 (en) | Growth Differentiation Factor-8 | |
Inoue et al. | A mouse line expressing Sall1‐driven inducible Cre recombinase in the kidney mesenchyme | |
WO1998033887A1 (fr) | Facteur-8 de differenciation de croissance | |
US6517835B2 (en) | Growth differentiation factor-11 | |
AU777420B2 (en) | Methods for manipulating the avian genome | |
WO1999040181A1 (fr) | Facteur-8 de differenciation de la croissance | |
US6514747B2 (en) | Agouti polynucleotide compositions and methods of use | |
JP2001501482A (ja) | トランスジェニック魚による組換えペプチドの製造 | |
US5843652A (en) | Isolation and characterization of Agouti: a diabetes/obesity related gene | |
JP2002511750A (ja) | in vivoにおいて内皮細胞に異種DNA配列を発現させる能力のある制御配列とその使用法 | |
US20080132445A1 (en) | Method for Inducing Mammary Epithelial Cell Differentiation | |
JP2010535496A (ja) | 乳腺特異的ヒトエリトロポエチン発現ベクター、これを用いた形質転換動物及びこれを用いたヒトエリトロポエチンの産生方法 | |
US20100107265A1 (en) | Double-muscling in mammals | |
Besenfelder et al. | Generation and application of transgenic rabbits | |
JP2002526034A (ja) | 増殖分化因子−11 | |
JPH10117785A (ja) | 動物における筋肉組織の増大 | |
JPH11239430A (ja) | トランスジェニック哺乳動物 | |
JP2003169679A (ja) | ヒトβ3受容体発現動物 | |
Meyn et al. | Preferential Overexpression of p53 in the Mammary Gland of Transgenic Mice Results in Altered Lobuloalveolar Development1 | |
JP2005187408A (ja) | 血管新生調節剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011210 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12N 15/00 B Ipc: 7C 07K 14/62 B Ipc: 7A 01K 67/027 A Ipc: 7C 07K 16/02 B |
|
17Q | First examination report despatched |
Effective date: 20040408 |
|
RTI1 | Title (correction) |
Free format text: METHODS FOR MANIPULATING THE AVIAN GENOME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060607 |